



Companies

Licensor
 Licensee

Potential Use

Disease Area
 Indication

Deal Financials

Potential Deal Size
 Upfront
 Milestones Total
 Milestones Regulatory
 Milestones Sales

Research Funding
 Profit Sharing Licensor
 Profit Sharing Licensee
 Royalties
 Equity

Compound

Compound Details
 Compound Name
 Development Stage

Territory
 Year of Deal Establishment
 Free Text Search

Filter Specification

252

OR

No.	Licensor	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln) Remarks	Milestones regulatory (mln) Amount	ilestone sales (mln) Rema...	Milestones sales (mln) Amount	Research Funding (mln) Remarks	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	Ro % s Re
127	ImmunoGen	per antibody target	2	per antibody target	40						0		0	0	
128	Immunomedics		18		290		65	one-off sales milestone if annual sales reach USD	50-225		0		0	0	
129	Incyte	INCB 18424	150	INCB 18424	1100	start F III INCB 18424	60				0		0	0	Tiered doubt
130	Inex Pharmaceutical Corporation		1.5		30.5						0		0	0	